Sun Pharma gets USFDA nod for generic drug to treat cardiac problems
As per IMS, Coreg CR had annual sales of around $208 million in the US for the 12 months ended August 2017
 "drugs, generics, drug, pharma, pharmaceuticals, medicines, tablets, capsules, healthcare, IPR")
Some major Western concerns about India’s patent framework are the definitions of inventions and provisions for compulsory licensing
Sun Pharmaceutical Industries on Thursday said its subsidiary has received approval from the US health regulator to market a generic version of GSK's Coreg CR, extended-release capsules in the American market.
One of the company's wholly-owned subsidiaries has received final approval from US Food and Drug Administration (USFDA) for the generic product in strengths of 10mg, 20mg, 40mg and 80 mg, Sun Pharma said in a statement.
Coreg CR extended-release capsules are indicated for treating various heart conditions, including heart failure and high blood pressure.
Also Read
As per IMS, Coreg CR had annual sales of around $208 million in the US for the 12 months ended August 2017.
Sun Pharma shares were trading 2.32 per cent up at Rs 535.40 apiece on BSE today.
Topics : Sun Pharma
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Oct 26 2017 | 3:38 PM IST